SK Life Science plots 2020 launch for now-approved seizure drug Xcopri

22nd November 2019 Uncategorised 0

Korean drugmaker SK Life Science is gearing up for a first launch early next year—provided the DEA cooperates. The company’s seizure drug Xcopri won FDA approval Thursday to treat partial-onset seizures in adults, and all that stands between it and a rollout is DEA scheduling.

More: SK Life Science plots 2020 launch for now-approved seizure drug Xcopri
Source: fierce